3 hours Cytokinetics (NASDAQ:CYTK) Earns “Overweight” Rating from Cantor FitzgeraldMarketBeat
Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research report on Friday.
XCantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research report on Friday.
X